Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Palisade Bio, Inc. held its 2026 annual stockholder meeting and made several governance and capital structure changes. Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and total authorized capital stock from 307,000,000 to 457,000,000 shares, effective upon filing in Delaware.
The company’s stockholders also approved amended and restated 2021 equity incentive and employee stock purchase plans, non‑binding executive compensation, and equity awards for non‑employee directors. A new independent director, Jordan Zwick, was appointed to the Board and Audit Committee, with an initial restricted stock unit grant valued at $566,000 vesting over three years.
Positive
- None.
Negative
- None.
Insights
Palisade Bio expands share capacity and refreshes incentives while adding an independent director.
Palisade Bio gained stockholder approval to raise authorized common shares to 450,000,000 and total capital stock to 457,000,000. This creates more headroom for future equity issuance, including under its amended and restated 2021 equity incentive and employee stock purchase plans.
The appointment of Jordan Zwick as an independent director and Audit Committee member, with a $566,000 restricted stock unit grant vesting over three years, aligns director pay with long‑term equity performance. Actual dilution and capital-raising impact will depend on how much of the new authorization the company ultimately issues.
8-K Event Classification
4 items: 5.02, 5.03, 5.07, 9.01
4 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Authorized common stock before: 300,000,000 shares
Authorized common stock after: 450,000,000 shares
Total authorized capital stock after: 457,000,000 shares
+5 more
8 metrics
Authorized common stock before
300,000,000 shares
Amended and Restated Certificate of Incorporation prior to June 11, 2026 amendment
Authorized common stock after
450,000,000 shares
Effective upon Delaware filing of Certificate of Amendment
Total authorized capital stock after
457,000,000 shares
Includes increased common stock authorization
Initial RSU grant to Jordan Zwick
$566,000
Grant value under non-employee director compensation policy
Record date shares outstanding
167,424,202 shares
Common stock outstanding as of April 15, 2026
Shares represented at meeting
129,904,054 shares
Approximately 77.59% of shares outstanding at record date
Votes for share increase amendment
128,093,623 votes
Proposal 3 to increase authorized common stock
Votes for equity incentive plan
92,245,546 votes
Proposal 4 approval of A&R 2021 Equity Incentive Plan
Key Terms
Amended and Restated Certificate of Incorporation, Equity Incentive Plan, Employee Stock Purchase Plan, Broker Non-Votes, +1 more
5 terms
Amended and Restated Certificate of Incorporation regulatory
"stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Equity Incentive Plan financial
"approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Employee Stock Purchase Plan financial
"approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Broker Non-Votes financial
"Votes For | Votes Against | Votes Withheld / Abstentions | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory basis regulatory
"Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
FAQ
Who is the new director appointed to Palisade Bio’s board?
The board appointed Jordan Zwick as a new director, expanding the board from five to six members. He will serve until the 2027 annual meeting, sits on the Audit Committee, and has been determined independent under Nasdaq and SEC rules.
What equity compensation will Jordan Zwick receive from Palisade Bio?
As a non-employee director, Jordan Zwick receives compensation under Palisade Bio’s non-employee director policy, including an initial restricted stock unit grant valued at $566,000. These restricted stock units vest in three equal annual installments over a three-year period.
Did Palisade Bio (PALI) stockholders approve the 2021 equity incentive plan changes?
Yes. Stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan. This plan, described in the company’s April 29, 2026 proxy statement, governs equity awards such as stock options and restricted stock units for eligible participants.
Was Palisade Bio’s employee stock purchase plan approved by stockholders?
Yes. Stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan. This plan, also detailed in the proxy statement, allows eligible employees to purchase company stock, typically at a discount, through payroll deductions within specified program terms.